Skip to main content
SpringerLink
Log in

Kidney Metastatic Bone Disease

  • Chapter
Metastatic Bone Disease

  • 1306 Accesses

Abstract

Renal cell carcinoma (RCC) is the eighth most common type of cancer in the USA with an estimated 13,860 deaths in 2014. Renal cell carcinoma represents a spectrum of tumors that are significantly different with respect to their cell type origin and type of genetic mutations. Metastatic lesions are quite common in RCC. They are found in one third of new cases and develop in 20–40 % patients after surgical treatment for localized disease. Historically, metastatic RCC (mRCC) has had a dismal prognosis. Currently, patients benefit from a multimodal and multispecialty treatment approach. Combination of surgical management consisting of cytoreductive nephrectomy and metastasectomy in a selected patient population followed by adjuvant therapy has been reported to achieve 5-year survival rates exceeding 70 %. Research of the von Hippel–Lindau tumor suppressor gene has led to better understanding of the RCC biology and development of novel therapeutic agents targeting specific molecules in the VHL signaling pathway. Targeted therapy has now become the adjuvant treatment of choice in mRCC. Numerous new treatment options for mRCC are currently being investigated in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. SEER Cancer Statistics Review 1975–2005. NCI 2007. http://seer.cancer.gov. Accessed 28 Apr 2014.

  2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–52.

    Article  PubMed  Google Scholar 

  3. Herr HW. A history of partial nephrectomy for renal tumors. J Urol. 2005;173:705–8.

    Article  PubMed  Google Scholar 

  4. Gati A, Kouidhi S, Marrakchi R, El Gaaied A, Kourda N, Derouiche A, Chebil M, Caignard A, Perier A. Obesity and renal cancer: role of adipokines in the tumor-immune system conflict. Oncoimmunology. 2014;3:e27810. Epub 2014 Jan 16.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E, Zbar B. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–3.

    Article  CAS  PubMed  Google Scholar 

  6. Lopez-Beltran A, Scarpelli M, Mention R, Kirkali Z. WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798–805.

    Article  PubMed  Google Scholar 

  7. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol. 2005;48:593–600.

    Article  PubMed  Google Scholar 

  8. Lau WK, Cheville JC, Blute ML, et al. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59:532–7.

    Article  PubMed  Google Scholar 

  9. Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Path. 1995;19:1–11.

    Article  PubMed  Google Scholar 

  10. Dason S, Allard C, Sheridan-Jonah A, Gill J, Jamshaid H, Aziz T, Kajal B, Kapoor A. Management of renal collecting duct carcinoma: a systematic overview and the McMaster experience. Curr Oncol. 2013;20:e223–232.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Lopez-Beltran A, Kirkali Z, Montironi R, Blanca A, Algaba F, Scarpelli M, Yorukoglu K, Hartmann A, Cheng L. Unclassified renal cell carcinoma: a report of 56 cases. BJU Int. 2012;110:786–93.

    Article  PubMed  Google Scholar 

  12. Brookman-May S, May M, Zigeuner R, Shariat SF, Scherr DS, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wieland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pahernik S. Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. J Urol. 2011;186:2175–81.

    Article  CAS  PubMed  Google Scholar 

  13. Collins E. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc UK. 1894;14:141–9.

    Google Scholar 

  14. Ev H. Ueber eine sehr seltene erkrankung der nethaut. Graefe Arch Ophthalmol. 1904;59:83–106.

    Article  Google Scholar 

  15. Lindau A. Zur frage der angiomatosis retinai und ihrer hirncomplikation. Acta Ophthalmol. 1927;4:193–226.

    Article  Google Scholar 

  16. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332:268–9.

    Article  CAS  PubMed  Google Scholar 

  17. Whaley JM, Naglich J, Gelbert L, et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet. 1994;55:1092–102.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Igarashi H, Esumi M, Ishida H, et al. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer. 2002;95:47–53.

    Article  CAS  PubMed  Google Scholar 

  19. Krieg M, Haas R, Brauch H, et al. Upregulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19:5435–543.

    Article  CAS  PubMed  Google Scholar 

  20. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004.

    Article  CAS  PubMed  Google Scholar 

  21. Lee TK, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12:5369–76.

    Article  CAS  PubMed  Google Scholar 

  22. Liu W, Shen SM, Zhao XY, Chen GQ. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol. 2012;3:165–78.

    PubMed Central  CAS  PubMed  Google Scholar 

  23. Banyra O, Tarchynets M, Shulyak A. Renal cell carcinoma: how to hit the targets? Cent Eur J Urol. 2013;66:394–404.

    Google Scholar 

  24. Curran MP. Temsirolimus: in advanced renal cell carcinoma. Drugs. 2008;68:631–8.

    Article  PubMed  Google Scholar 

  25. Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J. Molecular targeted therapies for solid tumors: management of side effects. Onkologie. 2009;32:129–38.

    PubMed  Google Scholar 

  26. Nanus DM, Pfeffer LM, Bander NH, et al. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of kidney-associated differentiation glycoprotein. Cancer Res. 1990;50:4190–4.

    CAS  PubMed  Google Scholar 

  27. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A. 1992;89:1428–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6 Suppl 1:S55–7.

    PubMed  Google Scholar 

  29. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–41.

    Article  CAS  PubMed  Google Scholar 

  30. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Fossa SD, Martinelli G, Otto U, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol. 1992;3:301–5.

    CAS  PubMed  Google Scholar 

  32. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859–67.

    CAS  PubMed  Google Scholar 

  33. Escudier B, Negrier S, Gravis G, Chevreau C, Delva R, Bay J, Geoffrois L, Legouffe E (2010) Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol. 28.

    Google Scholar 

  34. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Russo P, O’Brian MF. Surgical intervention in patients with metastatic renal cell carcinoma. Metastasectomy and cytoreductive nephrectomy. Urol Clin North Am. 2008;35:679–86.

    Article  PubMed  Google Scholar 

  36. Flanigan RC. Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res. 2004;10:6335s–41s.

    Article  PubMed  Google Scholar 

  37. Ognibene FP, Rosenberg SA, Lotze M, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 1988;94:750–4.

    Article  CAS  PubMed  Google Scholar 

  38. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7–20.

    CAS  PubMed  Google Scholar 

  39. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40.

    CAS  PubMed  Google Scholar 

  40. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–41.

    Article  PubMed  Google Scholar 

  41. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261–6.

    CAS  PubMed  Google Scholar 

  42. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314–9.

    Article  PubMed  Google Scholar 

  43. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577–84.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:1185–92.

    Article  PubMed  Google Scholar 

  45. Toyoda Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52:163–8.

    Article  PubMed  Google Scholar 

  46. Barney JD, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol. 1939;42:269–76.

    Google Scholar 

  47. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.

    Article  CAS  PubMed  Google Scholar 

  48. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120:148–52.

    CAS  PubMed  Google Scholar 

  49. Bloom HJ. Proceedings: hormone-induced and spontaneous regression of metastatic renal cancer. Cancer. 1973;32:1066–71.

    Article  CAS  PubMed  Google Scholar 

  50. Middleton Jr AW. Indications for and results of nephrectomy for metastatic renal cell carcinoma. Urol Clin North Am. 1980;7:711–7.

    PubMed  Google Scholar 

  51. Perut F, Cenni E, Unger RE, Kirkpatrick CJ, Giunti A, Baldini N. Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. Int J Oncol. 2009;34:1387–93.

    CAS  PubMed  Google Scholar 

  52. Wald G, Barnes KT, Bing MT, Kresowik TP, Tomanek-Chalkley A, Kucaba TA, Griffith TS, Brown JA, Norian LA. Minimal changes in the systemic immune response after nephrectomy of localized renal masses. Urol Oncol. 2014. pii: S1078-1439(14)00029-5 [Epub ahead of print].

    Google Scholar 

  53. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.

    Article  CAS  PubMed  Google Scholar 

  54. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158:1675–8.

    Article  CAS  PubMed  Google Scholar 

  55. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008;180:873–8.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873–82.

    Article  PubMed  Google Scholar 

  57. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

    Article  CAS  PubMed  Google Scholar 

  58. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  CAS  PubMed  Google Scholar 

  59. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–31.

    Article  CAS  PubMed  Google Scholar 

  60. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014. [Epub ahead of print].

    Google Scholar 

  61. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8.

    Article  CAS  PubMed  Google Scholar 

  62. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.

    Article  CAS  PubMed  Google Scholar 

  63. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  CAS  PubMed  Google Scholar 

  64. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552–62.

    Article  CAS  PubMed  Google Scholar 

  65. Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287–94.

    Article  CAS  PubMed  Google Scholar 

  66. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ, ARCC Global Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–8.

    Article  CAS  PubMed  Google Scholar 

  67. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.

    Article  CAS  PubMed  Google Scholar 

  68. Escudier B, Negrier S, Gravis G, Chevreau C, Delva R, Bay J, Geoffrois L, Legouffe E. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol. 2010;28:15s.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, University Hospital Salt Lake City, 50 Medical Drive, Salt Lake City, UT, 84132, USA

    Patrik Luzny MD

  2. Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, N6405, Salt Lake City, UT, 84112, USA

    Christopher Dechet MD, FACS

Authors
  1. Patrik Luzny MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher Dechet MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrik Luzny MD .

Editor information

Editors and Affiliations

  1. Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah, USA

    R. Lor Randall

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Luzny, P., Dechet, C. (2016). Kidney Metastatic Bone Disease. In: Randall, R. (eds) Metastatic Bone Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5662-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5662-9_7

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5661-2

  • Online ISBN: 978-1-4614-5662-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation